Evidence map›Paper›PMID 41373741›Full record

ReviewInternational journal of molecular sciences2025

Integrating Bioprinting and Increased Throughput: Next-Generation Models for Cardiac Research.

Stephanie Nguyen, Zachary Laksman

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stephanie NguyenSchool of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 2B9, Canada.ORCID 0000-0002-4443-3890
Zachary LaksmanSchool of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 2B9, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past two decades, three-dimensional cell culture (3DCC) and bioprinting (3DBP) technology have been at the forefront of developing engineered human cardiac tissue. Compared to 2D culture systems, 3DCC-based models more accurately replicate key characteristics of living tissues such as diffusion dynamics, interactions between cells and the extracellular matrix, as well as the presence of supporting stromal components. The rise of new 3DBP techniques serves to facilitate the robust and rapid generation of 3D tissue alongside real-time assessment of their characteristics. In order to capitalize on their translational potential, high-throughput screening (HTS) is required as research draws nearer to replicating clinical trials with cardiovascular-bioprinted tissues, and testing for the safety and efficacy of novel therapeutics. In this review, we summarize trending cardiac tissue models, as well as the state of their related or integrated HTS process and development. With an emphasis on the need for scale-up, compatibility, and standardization in HTS, the coalescence of 3DBP models and screening can provide improved disease modeling, drug efficacy, and toxicity testing.

Indexed as

BioprintingHigh-Throughput Screening AssaysTissue EngineeringAnimalsHumansMyocardiumPrinting, Three-Dimensional3D bioprinting3D cell culturecardiac tissuehigh-throughputintegrationmodels

Identifiers

PMID41373741
PMCPMC12692318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.